Q2 2026 Lexicon Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Lexicon Pharmaceuticals Inc (LXRX) completed enrollment in its Phase 3 SONATA HCM trial, which was significantly over-enrolled, potentially improving the study's statistical power.
- The company expects to meet all FDA criteria for resubmitting the Zynquista NDA, with DKA rates in the STENA-1 study similar to standard of care and below those seen in prior trials.
- Lexicon Pharmaceuticals Inc (LXRX) anticipates completing the Zynquista NDA resubmission in Q4 2026, with potential for a faster-than-standard FDA review.
- The company strengthened its balance sheet with a new $100 million debt facility from Hercules Capital, improving financial flexibility.
- Lexicon Pharmaceuticals Inc (LXRX) is advancing its pipeline, including LX-9851 for obesity with licensee Novo Nordisk, and has potential to receive a third $10 million milestone payment later this year.
- The company is exploring new high-value indications for pilavapidin, with preclinical data expected later this year.
- Lexicon Pharmaceuticals Inc (LXRX) reported a net loss of $31.8 million for Q2 2026, a significant decline from net income of $3.3 million in the same period of 2025.
- Total revenues dropped sharply to $0.7 million in Q2 2026 from $28.9 million in Q2 2025, primarily due to the absence of a one-time licensing fee from Novo Nordisk.
- The Zynquista NDA resubmission timeline was delayed to Q4 2026, slightly later than previously anticipated.
- The company incurred a $4.3 million loss on the early extinguishment of debt related to repaying its Oxford Finance term loans.
- Lexicon Pharmaceuticals Inc (LXRX) faces uncertainty regarding the commercial potential of sotagliflozin in HCM, as the trial includes a mix of obstructive and non-obstructive patients, and the exact patient breakdown on cardiac myosin inhibitors has not been disclosed.
- The company's cash position of $190.6 million may be insufficient to fund all operations and milestones without additional financing or successful commercialization.
Welcome to the Lexicon Pharmaceuticals Second Quarter 2026 Financial Results Conference Call.
At this time, all participants are in listen-only mode.
Following management's prepared remarks, we will hold a brief question-and-answer session.
As a reminder, this call is being recorded today, August 6, 2026.
I will now turn the call over to Lisa DeFrancesco, SVP, Investor Relations and Corporate Communications for Lexicon. Please go ahead, Lisa.
Thank you, Therese. Good morning and welcome to our second quarter 2026 earnings call. Joining me today are Dr. Mike Exton, Lexicon's Chief Executive Officer and Director, Dr. Craig Granowitz, Senior Vice President and Chief Medical Officer, and Scott Chianti, Senior Vice President and Chief Financial Officer.
This morning, Lexicon issued a press release announcing our financial results for the second quarter of 2026, which is available on our website at
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
